Giant cell tumor of tendon sheath in the wrist that damaged the extensor indicis proprius tendon: a case report and literature review

Zhao, Qingfang; Lü, Hui

doi:10.1186/s12885-019-6293-x

Cited by 10 publications

(9 citation statements)

References 22 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, there is no associated cancer in tendons. Giant cell tumor of the tendon sheath (GCTTS) very rarely impacts tendon proper [179]. One attractive hypothesis is that the tendon matrix environement regulated by EGR1 is protective against cancer.…”

Section: Discussionmentioning

confidence: 99%

EGR1 Transcription Factor is a Multifaceted Regulator of Matrix Production in Tendons and Other Connective Tissues

Havis

Duprez

2020

IJMS

396

View full text Add to dashboard Cite

Although the transcription factor EGR1 is known as NGF1-A, TIS8, Krox24, zif/268, and ZENK, it still has many fewer names than biological functions. A broad range of signals induce Egr1 gene expression via numerous regulatory elements identified in the Egr1 promoter. EGR1 is also the target of multiple post-translational modifications, which modulate EGR1 transcriptional activity. Despite the myriad regulators of Egr1 transcription and translation, and the numerous biological functions identified for EGR1, the literature reveals a recurring theme of EGR1 transcriptional activity in connective tissues, regulating genes related to the extracellular matrix. Egr1 is expressed in different connective tissues, such as tendon (a dense connective tissue), cartilage and bone (supportive connective tissues), and adipose tissue (a loose connective tissue). Egr1 is involved in the development, homeostasis, and healing processes of these tissues, mainly via the regulation of extracellular matrix. In addition, Egr1 is often involved in the abnormal production of extracellular matrix in fibrotic conditions, and Egr1 deletion is seen as a target for therapeutic strategies to fight fibrotic conditions. This generic EGR1 function in matrix regulation has little-explored implications but is potentially important for tendon repair.

show abstract

Section: Discussionmentioning

confidence: 99%

EGR1 Transcription Factor is a Multifaceted Regulator of Matrix Production in Tendons and Other Connective Tissues

Havis

Duprez

2020

IJMS

396

View full text Add to dashboard Cite

show abstract

“…Lesions frequently are localized to the tendon sheath, especially on the fingers and wrists, with no malignant tendency or propensity for spontaneous regression. 13 The local recurrence rate is as high as 45%, which is related to surgical resection insufficiency. 14 Histopathologic examination shows lobulated tumor tissue surrounded by dense fibrosis.…”

Section: The Best Diagnosis Ismentioning

confidence: 99%

Firm Digital Papulonodules in an Infant

Hu¹

2021

Cutis

View full text Add to dashboard Cite

Eligible for 1 MOC SA Credit From the ABD This Dermatopathology Diagnosis in our print edition is eligible for 1 self-assessment credit for Maintenance of Certification from the American Board of Dermatology (ABD). After completing this activity, diplomates can visit the ABD website (http://www.abderm.org) to self-report the credits under the activity title "Cutis Dermatopathology Diagnosis." You may report the credit after each activity is completed or after accumulating multiple credits.

show abstract

“…This disease has a wide clinical spectrum capable of affecting patients of all ages but most commonly occurs in young adult females with a median age of 40 years [ 2 , 5 , 6 ]. TGCT is divided according to the site of origin (intra- or extra-articular) and growth pattern: localized TGCT (L-TGCT), formerly known as giant cell tumor of tendon sheath or diffuse TGCT (D-TGCT), previously referred to as pigmented villonodular synovitis (PVNS) [ 3 , 7 – 9 ]. The worldwide incidence rate of TGCT (L-TGCT and D-TGCT combined) is estimated to be 43 per million, with the localized form being more prevalent than diffuse disease [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor

Bernthal¹,

Randall

Zeitlinger

et al. 2022

Case Reports in Orthopedics

View full text Add to dashboard Cite

Tenosynovial giant cell tumor (TGCT) is a rare neoplasm of the joint synovium that has a wide clinical spectrum including pain and stiffness in the affected joint, joint swelling, periarticular erosions, and cartilage loss, which can severely impact quality of life. The mainstay treatment for TGCT has been surgery involving partial or total synovectomy using arthroscopic or open techniques. However, surgical resection alone is associated with high recurrence rates, particularly in diffuse-TGCT (D-TGCT) cases. The 3 cases presented here summarize a combination approach (surgery+pexidartinib [tyrosine kinase inhibitor]) in patients with previously unresectable or inoperable D-TGCT. Case 1-Hip. A 29-year-old male was treated with pexidartinib prior to surgery, resulting in tumor reduction. A left total hip arthroplasty (THA) was then performed with a lack of recurrence in 12 months postoperative, and the patient currently on pexidartinib treatment. Case 2-Foot. A 35-year-old female, nearly a decade following a left foot mass resection, was treated with pexidartinib following disease recurrence. A decrease in soft tissue lesions at the midfoot and decreased marrow enhancement at the first metatarsal head were seen within 4–5 months of pexidartinib treatment; the patient is currently on pexidartinib (400 mg/day) with improved symptom control. Case 3-Knee. A 55-year-old male patient received pexidartinib pre- and postoperatively. A reduction in swelling and the size of the popliteal cyst was significant and maintained, with the synovial disease growing when pexidartinib was discontinued. Surgery and adjuvant therapy eliminated the disease as of the last follow-up visit (11 months postoperative). These cases provide a unique perspective based on tumor location, type/timing of treatment strategy, and patient outcomes. Optimal treatment strategies for this debilitating disease may entail utilizing a combination approach (surgery+systemic treatment) to reduce surgical morbidity and the risk of postoperative disease recurrence.

show abstract

Giant cell tumor of tendon sheath in the wrist that damaged the extensor indicis proprius tendon: a case report and literature review

Cited by 10 publications

References 22 publications

EGR1 Transcription Factor is a Multifaceted Regulator of Matrix Production in Tendons and Other Connective Tissues

EGR1 Transcription Factor is a Multifaceted Regulator of Matrix Production in Tendons and Other Connective Tissues

Firm Digital Papulonodules in an Infant

Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor

Contact Info

Product

Resources

About